Anzeige
Mehr »
Login
Montag, 31.03.2025 Börsentäglich über 12.000 News von 695 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A407W6 | ISIN: US52635N1037 | Ticker-Symbol:
NASDAQ
31.03.25
21:29 Uhr
25,570 US-Dollar
-0,300
-1,16 %
1-Jahres-Chart
LENZ THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
LENZ THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur LENZ THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
20.03.LENZ Therapeutics stock holds $38 target on FDA approval optimism4
20.03.Citi raises LENZ Therapeutics price target to $47, keeps Buy rating5
20.03.Lenz Therapeutics outlines Q4 2025 launch plans for LNZ100 amid FDA review progress2
19.03.LENZ Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans2
19.03.LENZ Therapeutics, Inc. - 10-K, Annual Report1
19.03.LENZ Therapeutics GAAP EPS of -$0.46 misses by $0.053
19.03.LENZ Therapeutics, Inc.: LENZ Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights152New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025 Upon FDA approval, commercial launch activities to commence immediately with...
► Artikel lesen
LENZ THERAPEUTICS Aktie jetzt für 0€ handeln
19.03.LENZ Therapeutics, Inc. - 8-K, Current Report1
18.03.TD Cowen lifts LENZ Therapeutics stock to buy, sets $60 target1
18.02.Citi maintains Buy on LENZ Therapeutics, target at $443
26.12.24LENZ Therapeutics (NASDAQ:LENZ) Trading Up 6.3% - Here's What Happened7
06.11.24LENZ Therapeutics GAAP EPS of -$0.382
06.11.24LENZ Therapeutics, Inc.: LENZ Therapeutics Reports Third Quarter 2024 Financial Results225New Drug Application (NDA) for LNZ100 for treatment of presbyopia accepted for review by the U.S. Food and Drug Administration (FDA); PDUFA target action date of August 8, 2025 CORXEL and...
► Artikel lesen
06.11.24LENZ Therapeutics, Inc. - 10-Q, Quarterly Report1
06.11.24LENZ Therapeutics, Inc. - 8-K, Current Report-
28.10.24LENZ Therapeutics' Investigational Drug For Age-Related Blindness Aces Pivotal China Trial, Analyst Says Data Readout May Strengthen Position For Ex-U.S. Partnerships1
28.10.24LENZ Therapeutics, Inc. - 8-K, Current Report-
28.10.24Why LENZ Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket1
28.10.24LENZ Therapeutics Reports Positive Phase 3 Results For LNZ100 In Presbyopia Trial In China3
28.10.24LENZ Therapeutics, Inc.: CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100193Primary endpoint was met with 74% of participants dosed with LNZ100 achieving three-lines or greater improvement at 3 hours post treatment,and maintaining their optimal distance visual acuity (i.e....
► Artikel lesen
Seite:  Weiter >>
23 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1